

Korlym[®] (mifepristone) – First-time generic

- On January 19, 2024, [Teva launched](#) an [AB-rated](#) generic version of Corcept Therapeutics' [Korlym \(mifepristone\)](#) 300 mg tablets.
- Korlym is approved to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
- Korlym carries a boxed warning for termination of pregnancy.
- Mifepristone is also available generically as a [200 mg tablet](#) indicated in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.